Imad Tarhoni, MD, PhD
Chicago,IL
Summary
Translational pathology and oncology scientist with integrated expertise in medicine, diagnostics development, biomarkers, and immune-oncology. Highly motivated results driven professional with integral leadership skills. Looking forward to advancing my career in diagnostics and precision medicine.
Overview
16
16
years of professional experience
Work History
Clinical Assay Development Scientist
Rush Cancer Center, Biomarkers Core
Chicago, IL
12.2019 - Current
· Developed a novel serological multiplexed test for COVID-19 diagnosis and monitoring.
· Characterized the molecular biomarkers for prognostication of cachexia in advanced NSCLC patients.
· Assisted in research and sample collection for Rush Precision Oncology and Genomic Program RUCC
· Defined the relationship between soluble immune checkpoints and resistant retinoblastoma and neuroblastoma.
· Implemented full laboratory automation for high-throughput biomarkers testing
· Analytically and clinically validated several tests and panels from diagnostics companies..
· Optimized and validated the use of dried blood spots (DBS) sample collection for cancer biomarkers & COVID-19 testing
· Identified the effects of COVID on diabetic complications (collaboration with Woodhull hospital, NY),
· Trained graduate, medical, and undergraduate students in various laboratory methods and protocols
Graduate Researcher
Rush University Medical Center, RUMC
Chicago, IL
09.2012 - 12.2019
· Identified novel neo-antigens as surrogate prognostic biomarkers of response to PD-1/-L1 inhibition in advanced stage NSCLC.
· Characterized the relationship between the EGFR-TKI resistant NSCLC and immunomodulation.
· Developed a novel prognostic serum test to evaluate autoantibodies in advanced stage NSCLC.
· Described the topography and dynamics of soluble immune- checkpoints in lung cancer
· Identified the prognostic relationship between circulating immune-regulators and response to PD-1/-L1 inhibition therapy in advanced stage NSCLC
· Assisted in the development of tumor organoids for precision oncology and experimental studies
· Characterized the relationship between histopathological biomarkers of EMT, Phenotypic plasticity, and angiogenesis for prognostication of early recurrence in localized NSCLC.
Resident Physician, Pathology
Tajoura Hospital/ National Heart Center
Tripoli, Libya
04.2007 - 06.2012
· Acquired up-to-date knowledge and training in the field of laboratory medicine.
· Provided patient care-related consultations to treating physicians and assisted physicians in interpreting laboratory tests.
· Trained medical students and nursing staff on clinical indication and interpretation of lab tests.
· Educated physicians and health care workers on significant scientific issues in laboratory medicine.
· Assisted in routine quality control testing and compliance with clinical /laboratory practice guidelines
· Instructed classes and laboratory sessions in clinical chemistry and genetics in the school of medicine and laboratory sciences at the University of Zawia,
· Provided inpatient and outpatient healthcare in surgery, internal medicine, and emergency department.
· Performed full case workups, management, and follow up
· Performed Advanced Cardiac and Trauma life support in emergency settings
· Performed basic surgical and interventional procedures
· Assisted in the antismoking clinic at the National Heart Center
Education
Ph.D. - Biochemistry, Immune-Oncology Biomarkers
Rush University
Chicago, IL12.2019
Master of Science - Biochemistry, Cancer Biomarkers
Rush University
Chicago, IL08.2014
M.D. - Medicine
University of Zawia, School of Medicine
Libya03.2007
Skills
- Assay Development
- Protein Characterization
- Preclinical Testing
- Specimen Processing
- Protocol Development
- Clinical Testing
- Biomarkers
- Research Management
- Data Operations
- Results Analysis
- Data Analytics
- Bioinformatics
- Operational Improvements
Publications
- Ash, Michelle K., Bhimalli, Pavan P., Cho, Byoung-Kyu, Mattamana, Basil Baby, Gambut, Stéphanie, Tarhoni, Imad, Fhied, Cristina L., Reyes, Anjelica F., Arivalagan Immanuel, Jaison Rathina Raj, Negrão, Fernanda, Goel, Renu, Beck, Todd L., Hope, Thomas J., Sha, Beverly E., Goo, Young Ah, Al-Harthi, Lena, Mamede, Joao I., Borgia, Jeffrey A., Kelleher, Neil L., Schneider, Jeffrey R., Bulk IgG Glycosylation Predicts COVID-19 Severity and Vaccine Antibody Response. Available at SSRN: https://ssrn.com/abstract=4088889 or http://dx.doi.org/10.2139/ssrn.4088889
- Fhied CL* , Tarhoni I* , Gerard D, Lewin GM, Moudgalya H, Schneider JR, Borgia JA. Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19. J Vis Exp. 2022 Feb 16;(180). doi: 10.3791/63352. PMID: 35253789. * contributed equally
- Skertich, N.J.; Chu, F.; Tarhoni, I.A.M.; Szajek, S.; Borgia, J.A.; Madonna, M.B. Expression of Immunomodulatory Checkpoint Molecules in Drug-Resistant Neuroblastoma: An Exploratory Study. Cancers 2022, 14, 751. https://doi.org/10.3390/cancers14030751
- Skertich NJ, Chu F, Tarhoni I A, Szajek S, Borgia JA, Madonna MB. Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study. Surg Open Sci. 2021 Jul 14;6:10-14. doi: 10.1016/j.sopen.2021.07.001. eCollection 2021 Oct.
- Nicole Yun, Sherin Rouhani, Christine Bestvina, Ethan Ritz, Brendan Gilmore, Imad Tarhoni, Jeffrey Borgia, Marta Batus, Philip Bonomi, Mary Fidler Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy. Cancers (Basel). 2021 Mar 20;13(6):1426. doi: 10.3390/cancers13061426.
- Imad Tarhoni, Connor J. Wakefield, Revathi Kollipara, Mary Jo Fidler, Marta Batus, Philip Bonomi, and Jeffrey A. Borgia. Relationship between Neoantigen-specific Autoantibodies and Clinical Outcomes in Advanced Stage NSCLC Patients Receiving PD-1/-L1 Directed Immune Checkpoint Inhibition. January 2021, Journal of Immunological Methods 490:112956 DOI: 10.1016/j.jim.2021.112956
- Imad Tarhoni, Cristina L. Fhied, Mark Pool, Michael J. Liptay, Philip Bonomi, Christopher W. Seder & Jeffrey A. Borgia (2018) Development of bead based multiplexed immunoassay for evaluation of midkine, syndecan-1, and ANGPTL4 in patient serum, Journal of Immunoassay and Immunochemistry, 39:1, 84-98, DOI: 10.1080/15321819.2018.1407338
- Othman, A.H., Tandon, M., Tarhoni, I., Borgia, J.A., & Pratap, J. (2017). Lung Cancer Stem Cells: Insights into Characterization and Regulatory Mechanisms. Current Molecular Biology Reports, 3, 247-253.
- Christopher W Seder, John C Kubasiak, Ravi Pithadia, Sanjib Basu, Cristina Fhied, Imad Tarhoni, Edgar Davila, Hanan Alnajjar, Gary W Chmielewski, William H Warren, Michael J Liptay, Jeffrey A Borgia. Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules. Ann Thorac Surg 2015 Aug 30;100(2):429- 36. Epub 2015 Jun 30.
- Imad Tarhoni, Cristina Fhied, David Gerard, Jeffrey A Borgia, Multiplexed Evaluation of Soluble Immune-checkpoint Molecules in Sera from Metastatic NSCLC Patients Receiving Immunotherapy. Millipore-Sigma, October 2021.
- Borgia, J.A., Tarhoni, I., & Fhied, C. (2020). Novel Serological Test for Immune Response to SARS-CoV-2 Virus. Corpus ID: 221374769.
Timeline
Clinical Assay Development Scientist
Rush Cancer Center, Biomarkers Core
12.2019 - Current
Graduate Researcher
Rush University Medical Center, RUMC
09.2012 - 12.2019
Resident Physician, Pathology
Tajoura Hospital/ National Heart Center
04.2007 - 06.2012
Ph.D. - Biochemistry, Immune-Oncology Biomarkers
Rush University
Master of Science - Biochemistry, Cancer Biomarkers
Rush University
M.D. - Medicine
University of Zawia, School of Medicine
Similar Profiles
Ashley SimsAshley Sims
Access Specialist II at Rush MD Anderson Cancer CenterAccess Specialist II at Rush MD Anderson Cancer Center
Estefania AlmarazEstefania Almaraz
Graduate Research Assistant at NMSU Cancer Outreach CoreGraduate Research Assistant at NMSU Cancer Outreach Core
Virginia CabreraVirginia Cabrera
Supervisor at Rush University Medical Center/Rush Oak ParkSupervisor at Rush University Medical Center/Rush Oak Park